SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC
Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups
Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for triple-negative disease
Efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors
Significance of gut microbiota in patients receiving CAR T cell immunotherapy
The RxPONDER trial and its impact on best clinical practice
WHO and St. Jude Children’s research hospital to dramatically increase global access to childhood cancer medicine
The global platform for access to childhood cancer medicines
Cancer medicine shortages for children around the world
OncoAlert and ecancer round up: SABCS 2021
INTEGRATE study: Treatment pathways, outcomes and resource use in patients with multiple myeloma
Silver linings: a qualitative study of desirable changes to cancer care during the COVID-19 pandemic